<p><strong>Renal impairment</strong>: No specific dose adjustment is needed in patients with mild or moderate renal impairment.<br />
<br />
<strong>Hepatic impairment</strong>: In patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily.<br />
<br />
<strong>Elderly patients (&ge;65 years)</strong>: No additional dose adjustments are recommended for elderly patients.<br />
<br />
<strong>Paediatric population</strong>: The safety and efficacy of Ruxolitinib in children and adolescents aged up to 18 years have not been established. No data are available</p>